Skip to main content
Equibles

GSA CAPITAL PARTNERS LLP

Position in FATE — Fate Therapeutics Inc

CIK 1362033 LONDON, X0
Back to FATE Full portfolio

Position in FATE

as of Jun 30, 2026 · filed Aug 6, 2026
Position Value
$303,120
-$55,537 QoQ
Shares Held
112,267
-62.4% QoQ
Ownership
0.094%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#54
of 156 holders
Holding Since
Dec 2022
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in FATE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. FATE ranks #107 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 IOVA
Iovance Biotherapeutics, Inc.
 655,318 $2,726,122
2 IMVT
Immunovant, Inc.
 65,267 $2,514,737
3 GOSS
Gossamer Bio, Inc.
 14,986,947 $2,472,846
4 AXSM
Axsome Therapeutics, Inc.
 9,419 $2,305,488
5 CABA
Cabaletta Bio, Inc.
 668,563 $2,079,230
6 MLTX
MoonLake Immunotherapeutics
 106,695 $2,077,351
7 ATYR
aTYR PHARMA INC
 3,454,863 $2,062,553
8 CORT
Corcept Therapeutics Inc
 23,257 $2,022,196

All Filings in FATE

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $303,120 112,267
2026-03-31 $358,657 298,881
2025-12-31 $209,372 213,645
2025-09-30 $391,640 310,826
2025-06-30 $287,528 256,722
2024-06-30 $867,451 264,467
2024-03-31 $383,727 52,279
2023-12-31 $160,831 43,003
2023-09-30 $537,269 253,429
2023-06-30 $925,391 194,410
2023-03-31 $1,199,337 210,410
2022-12-31 $589,578 58,432